Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Deep Vein Thrombosis Market Revenue Outlook: What CAGR Lies Ahead Through 2030?
The deep vein thrombosis market has shown consistent expansion over recent years. Projections indicate that it will increase from $1.09 billion in 2025 to $1.14 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 4.0%. Several factors have contributed to this historical growth, including a rise in the incidence of venous thromboembolism, an aging demographic adopting more sedentary lifestyles, an increase in hospital-based surgical procedures, greater accessibility of conventional anticoagulants, and heightened awareness regarding DVT complications.
The deep vein thrombosis market is projected to experience consistent expansion over the upcoming years. This market is anticipated to reach $1.37 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 4.7%. Factors contributing to this growth during the forecast period include advances in novel anticoagulant therapies, a rising preference for oral rather than injectable treatments, the expansion of homecare and remote monitoring services, an increase in preventive screening programs, and enhanced access via online pharmacies. Key trends anticipated in this period encompass the increasing adoption of direct oral anticoagulants, a move towards outpatient and home-based dvt management, a greater emphasis on early diagnosis and risk stratification, the growing application of minimally invasive interventional procedures, and the broadening of online and specialty pharmacy channels.
Get A Free Sample Report With In-Depth Market Insights:
Deep Vein Thrombosis Market Growth Factors Behind Sustained Expansion
The increasing number of individuals who require deep vein thrombosis (DVT) treatment is expected to propel the growth of the deep vein thrombosis market going forward. DVT treatment involves managing patients afflicted with deep vein thrombosis by using drugs such as anticoagulants and other medications that prevent the formation of new blood clots and keep existing blood clots from expanding, thus alleviating the disease condition. The rise in the number of patients seeking DVT treatment signifies an increase in the prevalence of deep vein thrombosis, which in turn demands products for DVT diagnosis, prevention, and treatment. For instance, in February 2023, according to the Centers for Disease Control and Prevention (CDC), a US-based national public health agency, an overall 900,000 people could be affected each year in the United States due to deep vein thrombosis, and between 60,000 and 100,000 Americans die each year from DVT or PE (pulmonary embolism). Therefore, the increasing number of individuals requiring deep vein thrombosis (DVT) treatment is driving the market.
Deep Vein Thrombosis Market Segment Trends And Revenue Contributors
The deep vein thrombosis market covered in this report is segmented –
1) By Drug Class: Anticoagulants, Inferior Vena Cava Filters, Other Drug Class
2) By Treatment: Surgery, Drugs, Other Treatments
3) By Mode Of Administration: Injectable, Oral, Other Modes Of Action
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By End User: Hospitals, Homecare, Specialty Clinics, Other End-users
Subsegments:
1) By Anticoagulants: Direct Oral Anticoagulants (DOACs), Vitamin K Antagonists, Low Molecular Weight Heparins, Unfractionated Heparin
2) By Inferior Vena Cava Filters: Retrievable IVC Filters, Permanent IVC Filters, Advanced IVC Filter Systems
3) By Other Drug Class: Thrombolytics, Antiplatelet Agents, Fibrinolytics, Combination Therapy
Deep Vein Thrombosis Market Industry Trends Fueling Future Revenue Growth
Major companies within the deep vein thrombosis market are prioritizing the formation of strategic partnerships to enable rapid deep vein thrombosis (DVT) diagnosis and boost their market profits. These collaborative efforts underscore a growing interest in utilizing AI and machine learning to enhance medical diagnostics, particularly for the quick and precise detection of DVT. For example, in November 2023, ThinkSono Ltd., a UK-based ultrasound AI company focused on DVT diagnosis, partnered with NYU Langone Health, a US-based academic medical center, to launch the initial clinical trial for innovative artificial intelligence (AI)-powered ultrasound software designed to facilitate more rapid and portable diagnosis of deep vein thrombosis (DVT). This partnership allows the ThinkSono Guidance System technology to leverage AI, potentially detecting DVT more swiftly, accurately, and affordably than conventional techniques. Researchers plan to use the ThinkSono Guidance System in addition to standard ultrasound scanning for patients with and without DVT. The performance of both approaches will be contrasted to evaluate and confirm the ThinkSono system’s accuracy. Furthermore, medical students from the NYU Grossman School of Medicine will assist in conducting the trial as part of their school’s practical research curriculum.
Deep Vein Thrombosis Market Competitive Landscape: Which Companies Lead The Industry?
Major companies operating in the deep vein thrombosis market are Abbott Laboratories, Bristol-Myers Squibb Company, Sanofi-Aventis U.S. LLC, Daiichi Sankyo Company Limited, Novartis AG, Mylan N.V., Bayer AG, Boehringer Ingelheim GmbH, Medtronic PLC, Hikma Pharmaceuticals PLC, Teva Pharmaceutical Industries Ltd., Stryker Corporation, Cook Medical Incorporated, Boston Scientific Corporation, Pfizer Inc., Johnson & Johnson, GlaxoSmithKline plc, Shire Pharmaceuticals, AstraZeneca PLC, Endo International plc
View The Full Deep Vein Thrombosis Market Report:
Deep Vein Thrombosis Market Geographic Landscape: Which Region Dominates Industry Growth?
North America was the largest region in the deep vein thrombosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global deep vein thrombosis market report during the forecast period. The regions covered in the deep vein thrombosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model